The present invention relates to an antibody that specifically binds to the N-terminal region of lysyl-tRNA synthetase exposed on the extracellular membrane and the use thereof. More specifically, the invention relates to a specific CDR (complementary) described in the present specification. Sex determining site) sequence, lysyl-tRNA synthetase (KRS, Lysyl-tRNA synthetase) N-terminal, an antibody or a fragment thereof that specifically binds to an epitope (epitope) containing the sequence of SEQ ID NO: 97, The present invention relates to a pharmaceutical composition for suppressing cancer metastasis of the above-mentioned antibody or fragment, for diagnosing cancer, and for preventing or treating diseases related to migration of immune cells. The antibody or fragment thereof according to the present invention is extremely excellent in specific binding ability to the KRS N-terminal region exposed on the extracellular membrane, and thus is effective in cancer diagnosis, and has anticancer and cancer metastasis. It has a suppressive effect and can be very usefully used for prevention and treatment of diseases related to migration of immune cells.本発明は、細胞外膜に露出されたリシル-tRNA合成酵素N-末端領域に特異的に結合する抗体とその利用に関するもので、より詳細には、本明細書で記載する特定のCDR（相補性決定部位）配列を有し、リシル-tRNA合成酵素（KRS、Lysyl-tRNA synthetase）N-末端の、配列番号97の配列を含むエピトープ（epitope）に特異的に結合する抗体又はその断片と、前記抗体又は断片のがん転移抑制用途、がんの診断用途及び免疫細胞の移動関連疾患の予防又は治療用薬学的組成物に対するものである。 本発明に係る抗体又はその断片は、細胞外膜に露出されるKRS N-末端領域への特異的結合能力が極めて優れているため、がん診断に効果があり、抗がん及びがん転移抑制効果があって、免疫細胞の移動関連疾患を予防及び治療について極めて有用に利用することができる。
